Immunogen

ELAHERE

Manufacturer:

Immunogen

Elahere HCPCS:

C9146

HCPCS Code Descriptor:

Injection, mirvetuximab soravtansine-gynx, 1 mg

Category:

C Code

Elahere NDCs:

No actively aligned NDCs found

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Elahere CPT Codes:

Potential CPT administration codes for Elahere can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Elahere:

ELAHERE is an Oncology drug manufactured by Immunogen and administered via the Intravenous route of administration. The C Code: C9146 is aligned to the drug ELAHERE.

ACCESS PRICING AND MORE BY REGISTERING

C9146 Added Date:

April 1, 2023

C9146 Effective Date:

July 1, 2023

C9146 Termination Date:

June 30, 2023

We have not yet identified a manufacturer source of Elahere billing and coding information.
Elahere patient assistance information can be found through ELAHERE Support Services at the URL: https://www.elahere.com/support
ELAHERE prescribing information can be found at the link below:
Information regarding ELAHERE’s side effects can be found at MedlinePlus